REIMAGINE 2 finds a small A1C advantage for CagriSema over semaglutide

What happened

Adults with type 2 diabetes and a BMI in the overweight or obesity range joined REIMAGINE 2, which tested CagriSema against each component and placebo. The weekly fixed-dose product pairs cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist.

Across 30 countries, 2,713 people entered this phase 3 study. Eligibility required metformin-treated type 2 diabetes with an A1C from 7.0% through 10.5%. Metformin could be paired with an SGLT2 inhibitor, and BMI had to be 25 or higher. Treatment lasted 68 weeks across several active and placebo arms.

For the primary endpoint, investigators compared the CagriSema formulation with 2.4 mg of both drugs against a 2.4 mg semaglutide dose. Mean A1C began at 8.2%. By week 68, the estimated declines were 1.91 points for the combination and 1.75 points for semaglutide. That left a 0.16-point advantage for CagriSema. Its 95% confidence interval extended from 0.05 through 0.27 points.

Adverse events affected 86.9% of participants in the higher-dose CagriSema group and 81.2% in the semaglutide 2.4 mg group. Gastrointestinal disorders were the most frequent events with active treatment. Overall, 95.7% of randomized participants finished the study and 87.6% were still on assigned treatment at week 68. Novo Nordisk funded the trial.

What it means

The combination met the study's statistical test for superiority over a full 2.4 mg dose of semaglutide on A1C. The size of that average advantage was modest. Both facts matter: the result was unlikely to be explained by chance under the trial's analysis, but the difference was 0.16 percentage points rather than a large separation.

REIMAGINE 2 also gives the CagriSema diabetes program its active-comparator test. REIMAGINE 1 used placebo in people not taking diabetes medicine, and REIMAGINE 3 used placebo in people already taking basal insulin. This trial provides the clearest evidence in the cluster about whether adding cagrilintide improved glucose control beyond semaglutide alone.

What it does not mean

The primary result does not establish that every patient would notice a meaningful difference, nor does it decide whether the extra A1C change is worth any difference in side effects, access or cost. The abstract does not provide enough detail to make a complete individual benefit-risk comparison.

The trial enrolled people already using metformin with or without an SGLT2 inhibitor. It does not establish comparative effectiveness in people without diabetes or in those at other treatment stages. It also was not designed to show fewer heart attacks, strokes, kidney failures or deaths.